ATRX and central nervous system cancer: In the present study, for the first time to our knowledge, we illustrated an evaluation formula for the evolution of gliomas by IDH1-R132H combined with ATRX immunohistochemistry and identified the association between IDH1-R132H/ATRX loss and longer progression time interval of gliomas.